

Docket No. DDI5016USNP

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**Applicants** 

Bryan Windus-Smith et al.

Confirmation No. 8222

Serial No.

1/666,154

Art Unit: 3728

Filed

09/19/2003

Examiner: Reynolds, Steven Alan

For

Medical Device Package, Kit and Associated Methods

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

(Name of applicant, assignee, or Registered Representative)

(Signature)

2 - 8 - 2007
(Date of Signature)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

#### THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This paper is supplemental to the Information Disclosure Statements mailed 09/19/2003, 01/11/2005 and 07/07/2006.

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

## Serial No. 11/666,154

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

In accordance with §1.97(b), since this Information Disclosure Statement is
being filed either within three months of the filing date of the above-identified national
application (other than a continued prosecution application under §1.53(d)), within three month
of the date of entry into the national stage of the above identified application as set forth in
§1.491, or before the mailing date of a first Office Action on the merits of the above-identified
application, or before the mailing date of a first Office Action after the filing of a request for
continued examination under §1.114, no additional fee is required.
☐ In accordance with §1.129(a), this Information Disclosure Statement is being
filed in connection with _ the first or _ second After Final Submission, therefore:
Statement in Accordance with §1.97(e) (attached); or
Please charge Deposit Account No. 10-0750/ / the fee of
\$180.00 as set forth in §1.17(p).
In accordance with §1.97(c), this Information Disclosure Statement is being
filed after the period set forth in §1.97(b) above but before the mailing date of either a Final
Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes
prosecution and that it is accompanied by one of:
Statement in Accordance with §1.97(e) (attached); or
Please charge Deposit Account No. 10-0750/ / the fee of
\$180.00 as set forth in §1.17(p).
In accordance with §1.97(d), this Information Disclosure Statement is being
filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance
under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for
consideration of this Information Disclosure Statement. Included are: Statement in Accordance
with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(n)

# Serial No. 11/666,154

	Copies of each of the references listed on the attached Form PTO-1449 are		
enclosed here	with.		
herewith EXC	Copies of references listed on the attached Form PTO-1449 are enclosed, CEPT THAT:		
	In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.		
	If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.		
in accordance	Copies of only foreign patent documents and non-patent literature are enclosed with 37 CFR 1.98 (a)(2).		
	There are no listed references which are not in the English language.		
as follows:	The relevance of those listed references which are not in the English language is		
which are liste	Attached are copies of search report(s) from corresponding patent application(s), ed on the attached Submission Under MPEP 609 D.		
may be deeme	Attached are the following non-published pending patent applications which ed relevant, which are listed on the attached Submission Under MPEP 609 D.		

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/ DDI5016USNP/MM.

Respectfully submitted,

Mayumi Maeda Reg. No. 40,075

Attorney for Applicants

Johnson & Johnson International Patent Law Division Attn: Philip S. Johnson, Esq. P.O. Box 1222 New Brunswick, NJ 08903 (408) 956-4790

DATED:

PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 1

a collection of information unless it displays a valid OMB control number.			
Application Number	11/666,154		
Filing Date	09/19/2003		
First Named Inventor	Bryan Windus-Smith		
Group Art Unit	3728		
Examiner Name	Reynolds, Steven Alan		
Attorney Docket Number	DDI5016USNP		

#### FOREIGN PATENT DOCUMENTS Foreign Patent Document Date of Publication Pages, Columns, Lines, of Cited Document where relevant Name of Patentee or Examiner Cite passages or relevant T<sup>6</sup> mm-dd-yyyy Applicant of Cited Document figures appear Initials Office<sup>3</sup> Number⁴ KindCode5 No.1 wo 97/10014 Α Needle Technology (Aust.) Limited 03/20/1997 wo 96/02290 Α Novo Nordisk A/S 02/01/1996

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
Approved for use through 10/31/2002. OMB 0651-0031

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.